← Back to home

PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS)

Clinical trials for PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS) explained in plain language.

Never miss a new study

Get alerted when new PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS) trials appear

Sign up with your email to follow new studies for PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Hope for rare eye disease: experimental gene therapy offered to control group

Disease control ENROLLING_BY_INVITATION

This study provides the ZVS101e injection to 32 people with Bietti crystalline corneoretinal dystrophy who were previously in a control group. The goal is to offer treatment and check for side effects. Participants must have completed a 52-week follow-up in an earlier phase 3 tri…

Matched conditions: PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS)

Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control

Last updated Apr 28, 2026 13:02 UTC

PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS)

Get alerted when new PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS) trials appear

Hope for rare eye disease: experimental gene therapy offered to control group